Atai Beckley N.V. (FRA:9VC)

Market Cap	708.00M
Revenue (ttm)	2.57M
Net Income (ttm)	-131.42M
Shares Out	n/a
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	2,353
Open	3.232
Previous Close	3.054
Day's Range	3.232 - 3.299
52-Week Range	1.021 - 5.980
Beta	n/a
RSI	38.84
Earnings Date	Nov 14, 2025

About Atai Beckley

Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizoph...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 54
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9VC

Financial Performance

In 2024, Atai Beckley's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.

Financial numbers in USD